Christopher Carey

Canopy Growth Inc. (NYSE: CGC) (TSE:WEED) recently announced its new product line amid Canada's "cannabis 2.0" launch this month. Here's what the sell-side thinks. The Analysts Bank of America Merrill Lynch's Christopher Carey reiterated a Buy rating on Canopy Growth and...

Canopy Growth Corp's (NYSE: CGC) shares have fallen 65% in the last six months. On Wednesday, the cannabis stock received an upgrade from Bank of America Merrill Lynch, which said Canopy is poised to meet Street expectations.  The Analyst Christopher Carey upgraded Canopy Growth from...

Over the last 12 months, Canopy Growth Corp  (NYSE: CGC) (TSE: WEED) shares have fallen 55%. The cannabis company reported second-quarter results Thursday, posting net revenue of CA$76.6 million ($84.2 million) and a net loss of CA$374.6 million.  The Analysts Bank of America Merrill...

Over the last six months, Canopy Growth Corp (NYSE: CGC) shares have fallen 65.45%.   The company released second-quarter results Thursday that sent the stock lower.  The Analysts Bank of America Merrill Lynch’s Christopher Carey reiterated a Neutral rating on Canopy...

Over the last six months, Cronos Group Inc. (NASDAQ: CRON) shares have fallen by  43.3%. The Analyst Bank of America Merrill Lynch’s Christopher Carey maintained a Buy rating on Cronos Group with a $13 price objective. The Thesis BofA's price objective for Cronos is based...

Over the past 12 months, Canopy Growth’s (NYSE: CGC) shares have fallen by half.  The Analyst Bank of America Merrill Lynch’s Christopher Carey reiterated a Neutral rating on Canopy Growth with a $23 price objective.  The Thesis The risk-reward profile for Canopy's second-...

HEXO Corp. (TSX: HEXO) (NYSE: HEXO) announced Friday that Chief Financial Officer Michael Monahan is resigning due to family reasons.  "Since joining HEXO Corp, it has become apparent that this job requires me to spend the majority of my time in Gatineau and in Ottawa. During this...

Scotts Miracle-Gro Co’s (NYSE: SMG) cannabis division seems poised for growth, while expectations seem to be low for the company’s performance in the fiscal fourth quarter, according to Bank of America Merrill Lynch. The Analyst BofA’s Christopher Carey upgraded Scotts Miracle-Gro...

A rough few months for Canopy Growth Corp (NYSE: CGC) investors got even worse on Friday when the stock was hit by a major Wall Street downgrade.  The Analyst Christopher Carey downgraded Canopy Growth from Buy to Neutral and cut the price target from $46 to $27. The Thesis Carey said he is...

Canadian cannabis company Aurora Cannabis Inc (NYSE: ACB) reported fourth-quarter results Wednesday that fell short of the company's own expectations and received a mixed review from two Street analysts. The Analysts Canaccord Genuity analyst Matt Bottomley maintained a...

Tobacco stocks were resilient on Wednesday after a series of negative headlines about the potential dangers of vaping and indications from President Donald Trump that a regulatory crackdown may be on the horizon. Vaping Crackdown On Wednesday morning, U.S. health secretary Alex Azar told reporters...

Cannabis stocks have been under pressure in recent months, as sales growth in the Canadian market hasn’t followed the explosive trajectory many investors had hoped. Bank of America Merrill Lynch analyst Christopher Carey said in a Thursday note that the latest Canadian cannabis volume...

Cronos Group Inc (NASDAQ: CRON) on Friday announced a $300 million buyout of U.S. CBD company Redwood Holdings, owner of CBD brand Lord Jones. Cronos shares traded lower by 5% in a weak market on Monday, but Bank of America analyst Christopher Carey said the buyout is a shrewd move by Cronos and...

Aurora Cannabis Inc (NYSE: ACB) deserves credit for building industry leading scale and strong margins, but Bank of America thinks the company is burning fast at a concerning pace. The Analyst Bank of America's Christopher Carey downgraded Aurora's U.S.-listed stock from Buy to Neutral with...

Cannabis stocks are taking a pounding on Friday, and have mostly been under pressure for the past month or so. For most of the past year, cannabis stocks have enjoyed strong positive momentum and favorable technical trends, but recent weakness has done significant damage to the near-term technical...